Shiyi Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shiyi Yin has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Jinlu Zhang
Chigenovo Corporation Limited, Beijing, China
2 shared publications- Jinyuan Wang
Beijing Visual Science and Translational Eye Research Institute (BERI), Beijing Tsinghua Changgung Hospital Eye Center, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China
2 shared publications - Wen Bin Wei
Beijing Tongren Eye Center, Beijing key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology&Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China
2 shared publications - Brenda Gallie
Department of Ophthalmology, University of Ottawa, Ottawa, Canada
1 shared publication Chuan Zhang
Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China
1 shared publication- Chuqiao Liang
Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 19 November 2025
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 264 (3) , 839-850
The role of full-field stimulus threshold in evaluating Bietti crystalline dystrophy
Purpose Visual functional testing methods are limited and cannot be well applied in all kinds of ocular diseases, especially those with low-vision. To determine whether full-field stimulus threshold (FST) is an effective method in evaluating Bietti crystalline dystrophy (BCD), with the capability in replacing other traditional visual functional methods, we designed the study. Methods This study was a prospective cross-sectional observational study, conducted from September 2022 to March 2023. It was a sub-study of Beijing Tongren Eye Disease Clinical Database Biobank. The study was conducted in Beijing Tongren Hospital, Capital Medical University. BCD patients who were diagnosed based on clinical features, validated by whole-exome sequencing were included. The normal volunteers were included as control group. All BCD patients underwent comprehensive evaluations, including FST, best-corrected visual acuity (BCVA), color vision, microperimetry, full-field electroretinography (ffERG), optical coherence tomography (OCT), multimodal imaging system and 4 self-reported questionnaires. The normal control group subjects only conducted FST examination. The correlation between FST and BCVA, and the differences of FST values between disease severity groups, were evaluated. The BCVA logistic regression model, FST model and hybrid model’s performance (area under the curve [AUC]) were tested in predicting disease severity. Results 43 BCD patients (40.60 ± 8.57 years, 22 female [51%]) and 36 normal volunteers (38.56 ± 12.42 years, 21 female [58%]) were included. FST showed a moderate correlation with BCVA scores. Stage 2 group exhibited notably lower FST values than the stage 3 group, while the severely diminished group showed remarkable lower FST values than the extinguished group. The hybrid model showed better performance (AUC = 0.9221 and 0.9496) than FST model (AUC = 0.9026 and 0.9429), better than BCVA model (AUC = 0.8549 and 0.8487) in predicting disease severity. Conclusions The FST serves as a useful indicator for evaluating visual function and predicting the severity of disease in patients with BCD. The clinical implementation of FST value will serve as an important assay in various ocular diseases, necessitating further validation studies prior to its application.
- 19 November 2025
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 264 (3) , 839-850
Open AccessThe role of full-field stimulus threshold in evaluating Bietti crystalline dystrophy
Purpose Visual functional testing methods are limited and cannot be well applied in all kinds of ocular diseases, especially those with low-vision. To determine whether full-field stimulus threshold (FST) is an effective method in evaluating Bietti crystalline dystrophy (BCD), with the capability in replacing other traditional visual functional methods, we designed the study. Methods This study was a prospective cross-sectional observational study, conducted from September 2022 to March 2023. It was a sub-study of Beijing Tongren Eye Disease Clinical Database Biobank. The study was conducted in Beijing Tongren Hospital, Capital Medical University. BCD patients who were diagnosed based on clinical features, validated by whole-exome sequencing were included. The normal volunteers were included as control group. All BCD patients underwent comprehensive evaluations, including FST, best-corrected visual acuity (BCVA), color vision, microperimetry, full-field electroretinography (ffERG), optical coherence tomography (OCT), multimodal imaging system and 4 self-reported questionnaires. The normal control group subjects only conducted FST examination. The correlation between FST and BCVA, and the differences of FST values between disease severity groups, were evaluated. The BCVA logistic regression model, FST model and hybrid model’s performance (area under the curve [AUC]) were tested in predicting disease severity. Results 43 BCD patients (40.60 ± 8.57 years, 22 female [51%]) and 36 normal volunteers (38.56 ± 12.42 years, 21 female [58%]) were included. FST showed a moderate correlation with BCVA scores. Stage 2 group exhibited notably lower FST values than the stage 3 group, while the severely diminished group showed remarkable lower FST values than the extinguished group. The hybrid model showed better performance (AUC = 0.9221 and 0.9496) than FST model (AUC = 0.9026 and 0.9429), better than BCVA model (AUC = 0.8549 and 0.8487) in predicting disease severity. Conclusions The FST serves as a useful indicator for evaluating visual function and predicting the severity of disease in patients with BCD. The clinical implementation of FST value will serve as an important assay in various ocular diseases, necessitating further validation studies prior to its application.
- Open Access
- 24 April 2024
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 9 (1) , 1-10
Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial
Bietti crystalline corneoretinal dystrophy is an inherited retinal disease caused by mutations in CYP4V2, which results in blindness in the working-age population, and there is currently no available treatment. Here, we report the results of the first-in-human clinical trial (NCT04722107) of gene therapy for Bietti crystalline corneoretinal dystrophy, including 12 participants who were followed up for 180–365 days. This open-label, single-arm exploratory trial aimed to assess the safety and efficacy of a recombinant adeno-associated-virus-serotype-2/8 vector encoding the human CYP4V2 protein (rAAV2/8-hCYP4V2). Participants received a single unilateral subretinal injection of 7.5 × 1010 vector genomes of rAAV2/8-hCYP4V2. Overall, 73 treatment-emergent adverse events were reported, with the majority (98.6%) being of mild or moderate intensity and considered to be procedure- or corticosteroid-related; no treatment-related serious adverse events or local/systemic immune toxicities were observed. Compared with that measured at baseline, 77.8% of the treated eyes showed improvement in best-corrected visual acuity (BCVA) on day 180, with a mean ± standard deviation increase of 9.0 ± 10.8 letters in the 9 eyes analyzed (p = 0.021). By day 365, 80% of the treated eyes showed an increase in BCVA, with a mean increase of 11.0 ± 10.6 letters in the 5 eyes assessed (p = 0.125). Importantly, the patients’ improvement observed using multifocal electroretinogram, microperimetry, and Visual Function Questionnaire-25 further supported the beneficial effects of the treatment. We conclude that the favorable safety profile and visual improvements identified in this trial encourage the continued development of rAAV2/8-hCYP4V2 (named ZVS101e).
- 24 April 2024
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 9 (1) , 1-10
Open AccessGene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial
Bietti crystalline corneoretinal dystrophy is an inherited retinal disease caused by mutations in CYP4V2, which results in blindness in the working-age population, and there is currently no available treatment. Here, we report the results of the first-in-human clinical trial (NCT04722107) of gene therapy for Bietti crystalline corneoretinal dystrophy, including 12 participants who were followed up for 180–365 days. This open-label, single-arm exploratory trial aimed to assess the safety and efficacy of a recombinant adeno-associated-virus-serotype-2/8 vector encoding the human CYP4V2 protein (rAAV2/8-hCYP4V2). Participants received a single unilateral subretinal injection of 7.5 × 1010 vector genomes of rAAV2/8-hCYP4V2. Overall, 73 treatment-emergent adverse events were reported, with the majority (98.6%) being of mild or moderate intensity and considered to be procedure- or corticosteroid-related; no treatment-related serious adverse events or local/systemic immune toxicities were observed. Compared with that measured at baseline, 77.8% of the treated eyes showed improvement in best-corrected visual acuity (BCVA) on day 180, with a mean ± standard deviation increase of 9.0 ± 10.8 letters in the 9 eyes analyzed (p = 0.021). By day 365, 80% of the treated eyes showed an increase in BCVA, with a mean increase of 11.0 ± 10.6 letters in the 5 eyes assessed (p = 0.125). Importantly, the patients’ improvement observed using multifocal electroretinogram, microperimetry, and Visual Function Questionnaire-25 further supported the beneficial effects of the treatment. We conclude that the favorable safety profile and visual improvements identified in this trial encourage the continued development of rAAV2/8-hCYP4V2 (named ZVS101e).
- Open Access
- 1 June 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (11) , 709
Quantitative analysis of functional filtering bleb size using Mask R-CNN
Background: Deep learning has had a large effect on medical fields, including ophthalmology. The goal of this study was to quantitatively analyze the functional filtering bleb size with Mask R-CNN. Methods: This observational study employed eighty-three images of post-trabeculectomy functional filtering blebs. The images were divided into training and test groups and scored according to the Indiana Bleb Appearance Grading Scale (IBAGS) system. Then, 70 images from the training group were used to train an automatic detection system based on Mask R-CNN and perform a quantitative analysis of the function bleb size. Thirteen images from the test group were used to evaluate the model. During the training process, left and right image-flipping algorithms were used for data augmentation. Finally, the correlation between the functional filtering bleb area and the intraocular pressure (IOP) was analyzed. Results: The 83 functional filtering blebs have similar morphological features. According to IBAGS, the functional filtering blebs have a high incidence of E1/E2, H1/H2, and V0/V1. Our Mask R-CNN-based model using the selected parameters achieves good results on the training group after a 200-epoch training process. All the Intersection over Union (IoU) scores exceeded 93% on the test group. The Spearman correlation coefficient between the area of functional filtering blebs and the IOP value was −0.757 (PConclusions: Deep learning is a powerful tool for quantitatively analyzing the functional filtering bleb size. This technique is suitable for use in monitoring post-trabeculectomy filtering blebs in the future.
- 1 June 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (11) , 709
Open AccessQuantitative analysis of functional filtering bleb size using Mask R-CNN
Background: Deep learning has had a large effect on medical fields, including ophthalmology. The goal of this study was to quantitatively analyze the functional filtering bleb size with Mask R-CNN. Methods: This observational study employed eighty-three images of post-trabeculectomy functional filtering blebs. The images were divided into training and test groups and scored according to the Indiana Bleb Appearance Grading Scale (IBAGS) system. Then, 70 images from the training group were used to train an automatic detection system based on Mask R-CNN and perform a quantitative analysis of the function bleb size. Thirteen images from the test group were used to evaluate the model. During the training process, left and right image-flipping algorithms were used for data augmentation. Finally, the correlation between the functional filtering bleb area and the intraocular pressure (IOP) was analyzed. Results: The 83 functional filtering blebs have similar morphological features. According to IBAGS, the functional filtering blebs have a high incidence of E1/E2, H1/H2, and V0/V1. Our Mask R-CNN-based model using the selected parameters achieves good results on the training group after a 200-epoch training process. All the Intersection over Union (IoU) scores exceeded 93% on the test group. The Spearman correlation coefficient between the area of functional filtering blebs and the IOP value was −0.757 (PConclusions: Deep learning is a powerful tool for quantitatively analyzing the functional filtering bleb size. This technique is suitable for use in monitoring post-trabeculectomy filtering blebs in the future.